Pacific Biosciences of California (PACB) – Analysts’ Recent Ratings Changes

Pacific Biosciences of California (NASDAQ: PACB) has recently received a number of price target changes and ratings updates:

• 2/25/2025 – Pacific Biosciences of California was upgraded by analysts at StockNews.com to a “sell” rating.
• 2/20/2025 – Pacific Biosciences of California had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $2.00 price target on the stock, down previously from $2.50.
• 2/18/2025 – Pacific Biosciences of California had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1.75 to $1.50. They now have a “neutral” rating on the stock.
• 2/14/2025 – Pacific Biosciences of California was upgraded by analysts at StockNews.com to a “sell” rating.
• 2/14/2025 – Pacific Biosciences of California had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $2.50 price target on the stock.
• 1/23/2025 – Pacific Biosciences of California had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $2.25 to $1.75. They now have a “neutral” rating on the stock.
• 1/9/2025 – Pacific Biosciences of California was upgraded by analysts at StockNews.com to a “sell” rating.

Pacific Biosciences of California Trading Down 0.7 %

NASDAQ PACB opened at $1.34 on Thursday. Pacific Biosciences of California, Inc. has a 12 month low of $1.16 and a 12 month high of $5.01. The stock has a 50-day simple moving average of $1.68 and a 200 day simple moving average of $1.79. The company has a current ratio of 9.74, a quick ratio of 8.64 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $366.98 million, a PE ratio of -0.82 and a beta of 1.86.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Thursday, February 13th. The biotechnology company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.20). The company had revenue of $39.22 million during the quarter, compared to analysts’ expectations of $39.20 million. Pacific Biosciences of California had a negative return on equity of 42.89% and a negative net margin of 200.40%. During the same period in the prior year, the business posted ($0.27) EPS. Research analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current year.

Insider Buying and Selling at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Michele Farmer sold 24,349 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $1.88, for a total value of $45,776.12. Following the completion of the transaction, the insider now directly owns 187,592 shares of the company’s stock, valued at approximately $352,672.96. The trade was a 11.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Oene Mark Van sold 34,405 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $2.03, for a total value of $69,842.15. Following the sale, the insider now directly owns 1,597,454 shares in the company, valued at approximately $3,242,831.62. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Pacific Biosciences of California

Institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning lifted its stake in Pacific Biosciences of California by 30.8% in the third quarter. Creative Planning now owns 32,409 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 7,629 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Pacific Biosciences of California by 0.6% during the third quarter. ARK Investment Management LLC now owns 33,406,401 shares of the biotechnology company’s stock worth $56,791,000 after acquiring an additional 193,947 shares during the period. Atria Investments Inc lifted its position in Pacific Biosciences of California by 85.7% in the 3rd quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 10,138 shares in the last quarter. Intech Investment Management LLC acquired a new position in Pacific Biosciences of California in the 3rd quarter worth $190,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Pacific Biosciences of California by 4.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,040,303 shares of the biotechnology company’s stock worth $3,469,000 after purchasing an additional 82,807 shares in the last quarter.

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.